Moderna Inc. Stock
€59.48
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Moderna
sharewise wants to provide you with the best news and tools for Moderna, so we directly link to the best financial data sources.
Financials
News
Roivant Sciences Q4 Earnings Call Highlights
Key Points
- Interested in Roivant Sciences Ltd.? Here are five stocks we like better.
- IMVT-1402 posted encouraging preliminary results in difficult-to-treat rheumatoid arthritis, with about 73%
Assembly Biosciences Touts HSV, Hepatitis D Catalysts at BofA Conference
Assembly Biosciences (NASDAQ:ASMB) Chief Medical Officer Anuj Gaggar outlined the company’s virology strategy and upcoming clinical priorities during a Bank of America-hosted discussion
The S&P 500's 3 Best-Performing Stocks so far in 2026
Fear is dominating global markets right now. With geopolitical tensions intensifying in the Middle East and capital rotating out of equities, the S&P 500 ETF (NYSEARCA: SPY) is down about 2% year
3 ETFs Catapulting Beyond the S&P to Start the Year
About a month into the new year, exchange-traded funds (ETFs) are beginning to build up enough of a performance record for 2026 to potentially differentiate themselves from the broader market. The
Moderna Pops 17%—Is There Life in MRNA, Down 90% from COVID High?
In a blast from the past, COVID-19 vaccine developer Moderna (NASDAQ: MRNA) just made headlines in 2026. Shares jumped up more than 17% on Jan. 13, Moderna's largest single-day up-move in over
This Stock Has Already Doubled This Year and Is Still Racing Towards a Major Catalyst
Moderna (NASDAQ: MRNA) has been on fire this year. As of this writing, the company's shares have slightly more than doubled to date. What's more, the biotech has an important catalyst on the
Should You Buy Moderna Before Aug. 5?
Moderna (NASDAQ: MRNA) stock skyrocketed in early pandemic days -- and the company became a household name -- as it launched its coronavirus vaccine. This first product, and one using the new
Moderna Has Some Key Approvals Ahead. Is the Stock a Buy?
Shares of Moderna (NASDAQ: MRNA) jumped during the COVID-19 pandemic, but when its COVID-19 vaccine revenue dried up, the stock slumped. However, the company has recently shown it isn't a one-trick
These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside Ahead
Despite economic headwinds and geopolitical tensions, equities have performed fairly well so far this year. The S&P 500 is up by a solid 8% to date. Some companies are doing an even more impressive
Does Moderna Need to Start Making Money?
Moderna (NASDAQ: MRNA) is best known for its COVID-19 vaccines, which were fast-tracked for approval in 2020 and subsequently generated tens of billions of dollars in revenue.
However, a lot has
Meet the Biotech Stock That's Trouncing Lilly, Merck, and Pfizer in 2026
Eli Lilly (NYSE: LLY), Merck (NYSE: MRK), and Pfizer (NYSE: PFE) are among the largest pharmaceutical companies in the world. The first focuses primarily on developing medicines for diabetes and
Got $2,000? These Biotech Stocks Are Worth Considering for Long-Term Growth
Some investors might choose to stay out of the famously volatile biotech industry right now, given that equities are already facing plenty of uncertainty that has rocked the market. However, even in
2 Healthcare Stocks That Could Soar Over the Next 5 Years
While the stock market is facing significant volatility right now, there is a decent chance it will still perform fairly well over the next five years. That's what we have come to expect from
Moderna Stock is Soaring. Is It Too Late to Buy?
Moderna (NASDAQ: MRNA) is best known for its coronavirus vaccine, a product that generated more than $18 billion in revenue at its peak in 2022 and helped drive the stock higher during the early
Moderna's Ups and Downs: Here's What You Need to Know Before Investing.
Moderna (NASDAQ: MRNA) soared into the spotlight during the pandemic thanks to its mRNA technology and its rapid development of a coronavirus vaccine. But it's those two elements that have weighed
Here's Why I Wouldn't Touch Moderna With a 10‑Foot Pole Until Its Next Growth Engine Is Clear
Moderna (NASDAQ: MRNA) became a household name during the coronavirus pandemic. There's a good reason for that: Its mRNA technology enabled the rapid development of a vaccine. The financial benefit
Why Moderna Stock Just Popped
Vaccine specialist Moderna (NASDAQ: MRNA) stock soared 5.5% through 12:55 p.m. ET Wednesday after The Wall Street Journal reported that the U.S. Food and Drug Administration will accept (note
Moderna: Stock to Avoid or Bad News Buy?
A few years ago, investors rushed to buy Moderna (NASDAQ: MRNA) stock. The biotech company had brought its coronavirus vaccine to market in less than a year and quickly saw earnings take off. The
Moderna: Stock to Avoid or Bad News Buy?
A few years ago, investors rushed to buy Moderna (NASDAQ: MRNA) stock. The biotech company had brought its coronavirus vaccine to market in less than a year and quickly saw earnings take off. The
Should You Buy Moderna Before Feb. 13?
Moderna (NASDAQ: MRNA) has been on fire this year, with the biotech's shares up by 39% through Feb. 6. This isn't due to the company's financial results. Moderna has yet to release its
This Stock Is Already Up 58% This Year. Is It a Buy?
The past few years have been challenging for Moderna (NASDAQ: MRNA) as the biotech has failed to maintain strong revenue growth from its coronavirus vaccine. The company's shares have significantly
Why Moderna Stock Surged Today
Shares of Moderna (NASDAQ: MRNA) popped on Wednesday after the biotech leader announced positive clinical trial results for its experimental skin cancer vaccine, developed with healthcare giant